Bladder Cancer – Pipeline Review, H2 2017 – Research and Markets

Cancer – Pipeline Review, H2 2017”
report has been added to Research
and Markets’

Bladder Cancer – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Bladder Cancer
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players
involved in therapeutic development for Bladder Cancer and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 10, 53, 52, 5, 63, 12 and
1 respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 7, 2, 10 and 3 molecules,

Bladder Cancer (Oncology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Bladder Cancer – Overview
  3. Bladder Cancer – Therapeutics Development
  4. Bladder Cancer – Therapeutics Assessment
  5. Bladder Cancer – Companies Involved in Therapeutics Development
  6. Bladder Cancer – Drug Profiles
  7. Bladder Cancer – Dormant Projects
  8. Bladder Cancer – Discontinued Products
  9. Bladder Cancer – Product Development Milestones
  10. Appendix

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Bladder
Cancer Drugs